The Readout Loud
362: A mother’s perspective on Sarepta’s gene therapy halt
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
We bring on a mother whose 7-year-old has Duchenne muscular dystrophy, and hear her thoughts on Sarepta’s decision to pull its treatment Elevidys from the market, following a request from the Food and Drug Administration. We also talk about a rare mega-round for a new oncology biotech and an emerging class of drugs aimed at helping people stay awake.